Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accendra HealthACH -0.95%59 EV-to-EBIT is 824.12 as of Jul. 23, 2026, which is 5695% above its 10-year median of 14.22. GuruFocus rates ACH with a GF Score™ of 59/100 and a GF Value™ of $5.45 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 94 Medical Distribution companies, Accendra Health ranks worse than 100% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Accendra Health's Enterprise Value for the quarter that ended in Mar. 2026 was $2,008 Mil.
Accendra Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accendra Health EV-to-EBIT Related Terms
Accendra Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Accendra Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Accendra Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accendra Health EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Accendra Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Accendra Health's EV-to-EBIT falls into.
Accendra Health's current Enterprise Value is $2,073 Mil.
Accendra Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accendra Health (ACH) has a EV-to-EBIT of 824.12 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Accendra Health and its competitors. This is 5695% above median its historical median of 14.22. According to the industry distribution chart, Accendra Health ranks #94 out of 94 companies in the Medical Distribution industry.
Is Accendra Health's EV-to-EBIT too high?
Accendra Health's current EV-to-EBIT of 824.12 is 5695% above median its 10-year median of 14.22. The Medical Distribution industry median EV-to-EBIT is 11.58. Accendra Health's value of 824.12 is 7016.8% above this industry median. Based on the distribution chart, Accendra Health ranks #94 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Accendra Health has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accendra Health's EV-to-EBIT compare to FOCL and YI?
According to the Medical Distribution industry distribution chart, Accendra Health ranks #94 out of 94 companies for EV-to-EBIT. This places Accendra Health in the lower half of its industry. The industry median EV-to-EBIT is 11.58. Accendra Health's value of 824.12 is 7016.8% above this benchmark. While the company's 10-year median is 14.22 vs. the industry median of 11.58, Accendra Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.58, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accendra Health's current EV-to-EBIT of 824.12 is 7016.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Accendra Health and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accendra Health's current EV-to-EBIT is 824.12, which is 5695% above median its own 10-year median of 14.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accendra Health stock overvalued right now?
Based on GuruFocus' analysis, Accendra Health (ACH) is currently considered Possible Value Trap. The stock's GF Value™ is $5.45, compared to a current price of $3.13 — trading 42.6% below its estimated fair value. The current EV-to-EBIT is 824.12, which is 5695% above median its 10-year median of 14.22 and 7016.8% above the Medical Distribution industry median of 11.58. Accendra Health's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Accendra Health (ACH), the current EV-to-EBIT is 824.12 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Accendra Health (ACH) Overvalued in 2026?
Based on GuruFocus' analysis, Accendra Health stock appears to be undervalued.
The current stock price of $3.13 is trading 42.6% below its estimated GF Value™ of $5.45.
GuruFocus considers Accendra Health to be Possible Value Trap.
Key valuation signals for ACH:
EV-to-EBIT: 824.12 (5695% above median its 10-year median of 14.22)
GF Value™: $5.45 vs. price of $3.13 (42.6% below fair value)
Industry Position: 7016.8% above the Medical Distribution median (#94 of 94)
No single metric tells the full story. See the ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
59GF Score
Get the complete analysis for ACH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACH has been successfully added to your 
